Volume 2, Issue 5, September 2014, Page: 71-74
Spectral-Fluorescent Properties of Serum as a Reliable Marker for Early Diagnosis of Sepsis
Igor Gerych, Surgery Department, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
Olga Bulavenko, Obstetrics and Gynecology Department, Pirogov Vinnytsia National Medical University, Vinnytsia, Ukraine
Lesya Ostapyuk, Obstetrics and Gynecology Department, Pirogov Vinnytsia National Medical University, Vinnytsia, Ukraine
Received: Aug. 7, 2014;       Accepted: Aug. 21, 2014;       Published: Aug. 30, 2014
DOI: 10.11648/j.jgo.20140205.11      View  3047      Downloads  135
Abstract
Poor worldwide outcome of sepsis treatment is related to the lack of effective methods for its rapid diagnosis. We suggest to use the method based on fluorescence spectroscopy studies in vitro and in vivo for diagnosis of sepsis and pre-septic conditions. Obtained by this method results are 24-48 hours ahead of the data from standard clinical and laboratory tests.
Keywords
Sepsis, Purulent-Septic Complications, Method of Fluorescence Spectroscopy
To cite this article
Igor Gerych, Olga Bulavenko, Lesya Ostapyuk, Spectral-Fluorescent Properties of Serum as a Reliable Marker for Early Diagnosis of Sepsis, Journal of Gynecology and Obstetrics. Vol. 2, No. 5, 2014, pp. 71-74. doi: 10.11648/j.jgo.20140205.11
Reference
[1]
Ya. Hruzunov and G.E. Dobretsov Albumin of blood serum in clinical medicine; Moscow: HEOTAR, 1998, 440.
[2]
O.V. Bulavenko, I.D. Gerych, L.R. Ostapyuk, A.S. Voloshinovskii, S.V. Myagkota and V.V. Vashcuk Modeling changes in blood serum in various diseases and medical events; Biomedical and biosocial anthropology, Vinnytsia , 2013; 20 February: 8–14.
[3]
O.V. Bulavenko and L.R. Ostapyuk Urgent postnatal diagnosis of septic complications in modern obstetrics; Journal of Morphology. Reports of Morphology, Vinnytsia, 2011; 17 (3 October): 666–669.
[4]
V. Gavrylov, M.Bydula and D.Furmanchuk Reduction effective concentrations of albumin as a marker between accumulation and binding toxic products in plasma during endogenous intoxication, in Albumin of blood serum in clinical medicine, Ya. Hruzunov and G.E. Dobretsov, Eds. Moscow: HEOTAR, 1998, pp. 132–139.
[5]
I. Gerych, L. Levytska, A.Voloshinovskii and S.Myagkota Fluorescent analysis as a method for diagnosis of sepsis; Bullet. of Lviv. University. Biology Series, Issue 32. Lviv: Lviv Ivan Franko Univ., 2003; pp. 23-30.
[6]
I.D. Gerych, L.R. Levytska, A.S.Voloshinovskii and S.V. Myagkota Fluorescent spectral model of sepsis in vitro; Math. sciences. conf. Current issues and abdominal septic surgery. Lviv, 2004; pp.111-112.
[7]
I.D.Gerych,L.R.Ostapyuk, V.V.Vashcuk, A. S.Voloshinovskii and S.V. Myagkota Prospects for diagnosis of sepsis and septic complications by fluorescence spectroscopy; Bullet. Ukr. med. stomat. Acad. Actual problems of modern medicine, Poltava, 2009; 9, 1 (25); pp. 248-256.
[8]
Pat. Ukraine № 76953 A61V 17/00 G01N 33/48, G01N 21/64 method for early diagnosis of septic complications by the method of fluorescence spectroscopy / I.D. Gerych, O.V. Bulavenko, L.R.Ostapyuk, A.S.Voloshinovskii, S.V. Myagkota applicant and patentee Vinnytsia National Medical University.-№ 201207441,appl.19.06.2012; publ. 25.01.2013, Bull. № 2.
[9]
P. Y. Bochud , M.P. Glauser and T. Calandra Antibiotics in sepsis; Intensive Care Med., 2001; 27; pp. 33-48.
[10]
J. Gabert, E. Beillard, Velden van der VHJ, Bi W, D. Grimwade, N. Pallisgaard, G. Barbany, G. Cazzaniga, J.M. Cayuela, H. Cave, F. Pane, JLE Aerts, D Dei Michel, X Thirion, V. Pradel, M. Gonzalez, S. Viehmann, M. Malec, G. Saglio and Dongen van JJM Standardization and quality control studies of «real-time» quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia; A Europe Against Cancer Program. Leukemia, Paris, 2003; 17 ; pp. 2318-2357.
[11]
M. Hafes, Ye F., K. Jackson, Z. Yang, J. E. Karp, E. Labourier, and C. D. Gocke Performance and clinical evaluation of a sensitive multiplex assay for the rapid detection of common NPM1 mutations; Journal of Molecular diagnostics, Paris, 2010; 12 (5) September ; pp. 629-635.
[12]
E. Hammond , K. Shaw, B. Carnley, S. P'ng, I. James and R. Herrmann Quantitative determination of JAK2 V617F by TaqMan. An absolute measure of averaged copies per cell that may be associated with the different types of myeloproliferative disorders; Journal of Molecular diagnostics, Paris, 2007; 9 (2) April ; pp. 242-248.
[13]
M. Llewelyn and J. Cohen Diagnosis of infection in sepsis; Intensive Care Med., 2001 ; 27 ; pp. 10-32.
[14]
I. Matot and C.L. Sprung Definition of sepsis; Intensive Care Med., 2001; 2; pp. 3-9.
[15]
M. Nauck, W. Marz, and H. Wieland Evaluation of the Roche Diagnostics LightCycler-Factor V Leiden mutation detection kit and the LightCycler-Prothrombin mutation detection kit; Clinical biochemistry, 2000; 33 (3); pp. 213-216.
[16]
E. C. Wolstencroft, K. Hanlon, L. W. Harries, G. R. Standen, A. Sternberg and S. Ellard Development of quantitative real-time polymerase-chain reaction assay for the detection of the of JAK2 V617F mutation disorders; Journal of Molecular diagnostics, 2007; 9 (1); pp. 42-46.
Browse journals by subject